BABA vs PRPL

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.30, indicating negative shareholders' equity. While the company has maintained a healthy gross margin of 40.44% and modest revenue growth of 9.10%, these are overshadowed by consistent net losses and a catastrophic 5-year price decline of 98.2%. The lack of a Graham Number or Intrinsic Value calculation is a direct result of the company's negative earnings and equity. Overall, the deterministic health scores signal a high risk of insolvency.